Teva Pharmaceutical Industries (NYSE:TEVA) Hits New 1-Year High – Here’s Why

Teva Pharmaceutical Industries Limited (NYSE:TEVA)’s stock price reached a new 52-week high during trading on Monday . The company traded as high as $22.17 and last traded at $22.16, with a volume of 5554103 shares trading hands. The stock had previously closed at $22.09.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on TEVA shares. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. UBS Group raised their price target on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Moderate Buy” and an average target price of $20.88.

Teva Pharmaceutical Industries Price Performance

The company has a fifty day moving average price of $17.97 and a two-hundred day moving average price of $17.60. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. The company has a market cap of $25.40 billion, a price-to-earnings ratio of -26.38, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79.

Insiders Place Their Bets

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. The trade was a 30.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.55% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently added to or reduced their stakes in TEVA. UMB Bank n.a. grew its holdings in Teva Pharmaceutical Industries by 555.6% during the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after acquiring an additional 2,067 shares during the last quarter. Smithfield Trust Co increased its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock valued at $50,000 after purchasing an additional 980 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth $50,000. Claro Advisors LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $52,000. Finally, Venturi Wealth Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at $60,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.